Avidity Biosciences Ownership | Who Owns Avidity Biosciences?
Avidity Biosciences Ownership Summary
Avidity Biosciences is owned by 32.09% institutional investors, 5.18% insiders, and 62.73% retail investors. Fmr is the largest institutional shareholder, holding 13.38% of RNA shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 4.23% of its assets in Avidity Biosciences shares.
RNA Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Avidity Biosciences | 32.09% | 5.18% | 62.73% |
Sector | Healthcare Stocks | 57.43% | 9.41% | 33.16% |
Industry | Biotech Stocks | 69.02% | 8.92% | 22.06% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Fmr | 16.51M | 13.38% | $480.10M |
Rtw investments, lp | 8.81M | 10.10% | $359.76M |
Blackrock | 8.62M | 9.89% | $352.23M |
Price t rowe associates inc /md/ | 11.04M | 8.95% | $321.13M |
Blackrock funding, inc. /de | 9.93M | 8.05% | $288.83M |
Vanguard group | 9.43M | 7.64% | $274.28M |
Wellington management group llp | 8.11M | 6.57% | $235.73M |
Avoro capital advisors | 7.50M | 6.08% | $218.10M |
Janus henderson group | 7.05M | 5.72% | $205.13M |
Ra capital management | 6.30M | 5.11% | $183.22M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Alethea capital management | 420.87K | 10.48% | $12.24M |
Rtw investments, lp | 8.81M | 5.57% | $359.76M |
Propel bio management | 178.50K | 5.16% | $5.19M |
Casdin capital | 2.04M | 3.96% | $59.47M |
Boxer capital | 1.73M | 3.72% | $70.56M |
Silverarc capital management | 543.65K | 3.46% | $15.81M |
Avoro capital advisors | 7.50M | 3.08% | $218.10M |
Bioimpact capital | 702.98K | 2.90% | $20.44M |
Ra capital management | 6.30M | 2.44% | $183.22M |
Cormorant asset management, lp | 1.05M | 1.68% | $30.53M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Blackrock | 8.62M | 0.01% | 2.46M |
Janus henderson group | 7.05M | 0.10% | 2.16M |
Polar capital | 1.11M | 0.27% | 1.11M |
Wellington management group llp | 8.11M | 0.04% | 1.08M |
Rtw investments, lp | 8.81M | 5.57% | 836.57K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Cowen and company | - | - | -5.13M |
Nuveen asset management | 352.50K | 0.00% | -706.06K |
5am venture management | - | - | -665.55K |
D. e. shaw | 558.97K | 0.01% | -549.68K |
Lord, abbett | - | - | -539.21K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Polar capital | 1.11M | 0.27% | 1.11M | $45.51M |
Norges bank | 724.79K | 0.00% | 724.79K | $21.08M |
Artal group | 655.55K | 0.68% | 655.55K | $26.78M |
Finepoint capital lp | 391.30K | 0.69% | 391.30K | $11.38M |
Qube research | 223.76K | 0.01% | 223.76K | $6.51M |
Sold Out
Holder | Change |
---|---|
Hollencrest capital management | -10.00 |
Park place capital | -12.00 |
Nelson, van denburg & campbell wealth management group | -15.00 |
Capital performance advisors llp | -21.00 |
Cwm | -22.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 106 | -57.77% | 39,596,419 | -68.40% | 32 | 0.31% | 62 | -60.00% | 30 | -52.38% |
Sep 30, 2024 | 250 | 26.26% | 125,295,284 | 11.90% | 101 | 0.62% | 154 | 19.38% | 63 | 28.57% |
Jun 30, 2024 | 198 | 22.98% | 111,975,611 | 25.39% | 128 | 1.22% | 129 | 44.94% | 49 | - |
Mar 31, 2024 | 161 | 9.52% | 89,302,004 | 17.64% | 102 | 0.95% | 89 | 14.10% | 49 | 6.52% |
Dec 31, 2023 | 147 | 2.08% | 75,911,779 | -7.12% | 103 | 0.85% | 78 | -2.50% | 46 | 17.95% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Fidelity Growth Compy Commingled Pl S | 5.05M | 4.23% | 100.91K |
Fidelity Growth Compy Commingled Pl O | 4.86M | 4.11% | -69.00K |
US Small-Cap Growth II Equity Comp | 4.43M | 3.71% | -51.14K |
T. Rowe Price New Horizons | 4.43M | 3.71% | - |
Vanguard Total Stock Mkt Idx Inv | 3.54M | 2.97% | 8.62K |
Fidelity Growth Company Fund | 3.49M | 2.92% | -40.23K |
iShares Russell 2000 ETF | 2.89M | 2.41% | -56.58K |
T. Rowe Price Health Sciences | 2.44M | 2.05% | -200.29K |
Vanguard Health Care Inv | 2.35M | 1.97% | - |
SPDR® S&P Biotech ETF | 1.90M | 1.58% | 14.32K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Mar 11, 2025 | Flanagan W. Michael | Chief Scientific Officer | Sell | $602.61K |
Mar 03, 2025 | Gallagher Kathleen P. | Chief Program Officer | Sell | $172.81K |
Feb 03, 2025 | Gallagher Kathleen P. | Chief Program Officer | Sell | $188.92K |
Jan 21, 2025 | LEVIN ARTHUR A | - | Sell | $53.54K |
Jan 21, 2025 | MacLean Michael F | Chief Financial Officer | Sell | $46.38K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | 18 |
2024 Q4 | - | 14 |
2024 Q3 | - | 14 |
2024 Q2 | - | 18 |
2024 Q1 | - | 12 |
RNA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools